Single-Dose Drug Decreases Bone Loss in Newly Treated HIVSingle-Dose Drug Decreases Bone Loss in Newly Treated HIV

A single dose of zoledronic acid given at the start of ART decreases bone loss over the course of 48 weeks in HIV, according to a small, single-center, proof-of-concept study. Medscape Medical News
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news